All News

Frontline Zejula maintenance therapy decreased the risk of disease progression or death in patients with newly diagnosed ovarian cancer.

Cost burdens are prevalent among patients with metastatic prostate cancer; however, utilizing appropriate resources could reduce costs up to 100%.

The treatment combination of Rybrevant and chemotherapy significantly improved progression-free survival rates for patients newly diagnosed with metastatic NSCLC with EGFR Exon 20 insertion mutations.

After recovering from a bone marrow transplant to tackle a recurrence of acute myeloid leukemia, I started to volunteer.

Rivoceranib plus Airuika demonstrates improvement for survival in patients with unresectable hepatocellular carcinoma, a subset of liver cancer.

Therapies that target specific characteristics on kidney cancer cells are showing promise in the space, an expert explained.

Patients with MPNs can potentially experience long asymptomatic periods, and it’s up to patients and providers to remain vigilant as they monitor and manage symptoms.

Having a strong connection with their care team can be crucial for the well-being of LGBTQ+ patients with cancer, as a colorectal cancer survivor and surgeon from City of Hope told CURE®.

Most of us dread, simply dread, hearing the words, “I’m sorry you have cancer.” I did.

With new treatments being explored, it’s an exciting time for patients with kidney cancer, an expert explained.

An expert explained what aspects of a patient’s disease cancer care teams use to determine the best treatment options for patients with clear cell renal cell carcinoma.

This particular designation may expedite the process of approving Xpovio for the treatment of patients with myelofibrosis to address an unmet medical need.

Implementing longer intervals between the completion of neoadjuvant therapy and surgery may have a positive effect on pathologic complete responses for patients with locally advanced rectal cancer.

Even though I did smoke cigarettes, I made sure that I didn't smoke enough to get cancer from it.

Patients with BAP1-mutated renal cell carcinoma who were treated with Lynparza obtained responses with favorable side effect profiles.

A recent study has determined that Xospata plus chemo is safe for the treatment of relapsed/refractory acute myeloid leukemia with an FLT3 mutation.

A patient with glioblastoma, a type of brain cancer, was dosed with a novel combination immunotherapy as part of a phase 2b trial.

Patients with advanced ovarian cancer who achieved complete cytoreduction had the best outcomes, regardless of the number of chemotherapy cycles before surgery.

Being told to write was the best advice I could have ever received.

A randomized clinical trial, CHEERS, determined that the combination of stereotactic body radiotherapy (SBRT) and immune checkpoint inhibitors (ICIs) were ineffective as treatment for patients with advanced solid tumors.

An expert gives an overview of up-and-coming treatments for patients with kidney cancer.

Long-term follow-up data showed that Lenvima plus Keytruda continued to show benefit in patients with metastatic kidney cancer.

Immunotherapy combinations tended to improve outcomes for patients with metastatic kidney cancer who go on to receive surgery.

I couldn't believe that I would benefit from some of the side effects of my cancer treatment.

Radiation is an emerging treatment modality in kidney cancer. Research shows that it is effective and helps patients maintain a good quality of life.

Keytruda after nephrectomy improved disease-free survival rates in patients with clear cell renal cell carcinoma regardless of disease risk or stage.

Responses to treatment with Lenvima plus Keytruda for advanced renal cell carcinoma were present regardless of PD-L1 status.

One side effect of chemotherapy that no one warned me about was frequent urination.

From Stand Up to Cancer honoring survivors at a Minor League baseball game, to Maria Menounos showing her cancer scars on Instagram, here’s what’s happening in the oncology space this week.

A new study identified the elements that could determine the overall survival of patients with the metastatic eye tumor, uveal melanoma.